Biophytis receives Brazilian approval for Phase 2 obesity trial of BIO101

ImmuPharma selects Kymos Group as bioanalytical partner for Kapiglucagon

Neurocrine Biosciences initiates Phase 1 study of GLP-1/GIP/glucagon receptor triple agonist

Akeso Advances reports first patient dosed in AK146D1 combined with ivonescimab breast cancer study

Alebund's AP301 NDA accepted for review by China's NMPA

BioInvent receives FDA Fast Track designation for BI-1808 in ovarian cancer

NeuroSense completes PrimeC Pre-NDS process for potential December 2026 filing with Health Canada

Roche expands cyclospora testing portfolio to support US public health response

Olio Labs reveals study demonstrating AI-driven in vivo platform can predict clinical trial outcomes

Innovent doses first colorectal cancer patient with IBI363/TAK-928 in combination with bevacizumab

Galibra Neuroscience's SSADH deficiency gene therapy receives FDA Orphan Drug and Rare Pediatric Disease Designations

Obsidian Therapeutics advances Agni-01 study with first patient enrolled in registration-enabling cohort

Summit Therapeutics expands ivonescimab programme into bladder cancer with Phase II/III trial

Phylo partners with Chugai to advance AI agents in drug discovery

Lilly secures FDA Breakthrough Therapy designation for olomorasib in pancreatic cancer